Dr. Xiao-Jian Zhou PhD, is currently an executive director of clinical pharmacology & early medical development at Idenix Pharmaceuticals, Inc. in Cambridge, MA. He received his bachelor’s degree in pharmaceutical sciences from China Pharmaceutical University in 1985 and PhD in Pharmacology from the Université de la Mediterranée (Aix-Marseille II) in France in 1992. He then became a post-doctoral fellow in the Department of Clinical Pharmacology at the University of Alabama at Birmingham (UAB) and later a Research Assistant Professor. In 2001, Dr. Zhou joined Idenix Pharmaceuticals where he assumes responsibility of clinical pharmacology for all development programs of candidates against life-threatening human viral diseases including HBV (telbivudine: Tyzeka/Sebivo), HCV and HIV. Dr. Zhou has 20 years of experiences in clinical research especially in strategic integration of clinical pharmacology into drug development processes. He has authored/co-authored over 50 peer-reviewed papers and numerous meeting presentations.